Savara Inc (NASDAQ:SVRA - Get Free Report)'s share price traded up 4.1% on Tuesday . The company traded as high as $3.05 and last traded at $3.02. 101,330 shares were traded during trading, a decline of 92% from the average session volume of 1,328,423 shares. The stock had previously closed at $2.90.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Savara in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Savara currently has a consensus rating of "Moderate Buy" and an average target price of $8.83.
Read Our Latest Research Report on SVRA
Savara Stock Performance
The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. The stock has a market cap of $519.63 million, a PE ratio of -7.00 and a beta of 0.52. The firm has a fifty day moving average price of $2.74 and a 200 day moving average price of $3.09.
Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter. Research analysts forecast that Savara Inc will post -0.45 earnings per share for the current fiscal year.
Institutional Trading of Savara
Several large investors have recently bought and sold shares of the stock. Cibc World Markets Corp acquired a new stake in shares of Savara during the fourth quarter worth $33,000. XTX Topco Ltd purchased a new stake in Savara during the 4th quarter valued at about $34,000. Ameriprise Financial Inc. acquired a new position in shares of Savara in the fourth quarter valued at about $37,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Savara during the fourth quarter worth about $41,000. Finally, Hsbc Holdings PLC purchased a new stake in Savara in the fourth quarter valued at approximately $48,000. Hedge funds and other institutional investors own 87.93% of the company's stock.
About Savara
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
